AMBRX, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2003-01-01

Employees: 101

Market Cap: -

Website: http://www.ambrx.com

Clinical Trials

5

Active:1

Completed:2

Trial Phases

2 Phases

Phase 1:2

Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2

3 (60.0%)

Phase 1

2 (40.0%)

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Phase 2

Withdrawn

Conditions: HER2 Mutation-Related Tumors
HER2 Amplified Solid Tumors

Interventions: Drug: ARX788

First Posted Date: 2021-09-13

Last Posted Date: 2022-09-13

Lead Sponsor: Ambrx, Inc.

Registration Number: NCT05041972

Locations: 🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸
AMR Kansas City, Kansas City, Missouri, United States

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Phase 2

Recruiting

Conditions: HER2 Positive Metastatic Breast Cancer

Interventions: Drug: ARX788

First Posted Date: 2021-04-02

Last Posted Date: 2025-01-20

Lead Sponsor: Ambrx, Inc.

Target Recruit Count: 71

Registration Number: NCT04829604

Locations: 🇰🇷
Research Site, Suwon, Korea, Republic of

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Phase 1

Completed

Conditions: Gastric Neoplasm
Solid Tumors
Breast Neoplasms

Interventions: Drug: ARX788

First Posted Date: 2017-08-21

Last Posted Date: 2024-02-01

Lead Sponsor: Ambrx, Inc.

Target Recruit Count: 106

Registration Number: NCT03255070

Locations: 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸
UCLA Hematology-Oncology, Santa Monica, California, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Phase 2

Completed

Conditions: Growth Hormone Deficiency

Interventions: Drug: ARX201

First Posted Date: 2008-10-23

Last Posted Date: 2009-10-12

Lead Sponsor: Ambrx, Inc.

Target Recruit Count: 36

Registration Number: NCT00778518

Locations: 🇭🇺
Accelsiors CRO and Consultancy Services, Budapest, Hungary

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.